Pds biotech provides business update and reports third quarter 2021 financial results

Florham park, n.j., nov. 10, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, will discuss its financial results for the quarter ended september 30, 2021 and provide a business update on its conference call today.
PDSB Ratings Summary
PDSB Quant Ranking